Compare Aventis Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs CIPLA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA CIPLA SANOFI INDIA/
CIPLA
 
P/E (TTM) x 42.7 33.3 128.2% View Chart
P/BV x 7.8 3.4 227.9% View Chart
Dividend Yield % 1.1 0.5 237.4%  

Financials

 SANOFI INDIA   CIPLA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
CIPLA
Mar-19
SANOFI INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs6,840678 1,008.9%   
Low Rs4,630484 957.0%   
Sales per share (Unadj.) Rs1,203.1198.2 607.0%  
Earnings per share (Unadj.) Rs165.318.5 892.2%  
Cash flow per share (Unadj.) Rs209.935.0 599.8%  
Dividends per share (Unadj.) Rs84.003.00 2,800.0%  
Dividend yield (eoy) %1.50.5 283.6%  
Book value per share (Unadj.) Rs963.6186.3 517.2%  
Shares outstanding (eoy) m23.03805.70 2.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.82.9 162.7%   
Avg P/E ratio x34.731.4 110.7%  
P/CF ratio (eoy) x27.316.6 164.6%  
Price / Book Value ratio x6.03.1 190.9%  
Dividend payout %50.816.2 313.8%   
Avg Mkt Cap Rs m132,078468,031 28.2%   
No. of employees `0003.322.6 14.6%   
Total wages/salary Rs m4,06828,565 14.2%   
Avg. sales/employee Rs Th8,393.87,053.1 119.0%   
Avg. wages/employee Rs Th1,232.41,261.5 97.7%   
Avg. net profit/employee Rs Th1,153.0659.1 174.9%   
INCOME DATA
Net Sales Rs m27,708159,710 17.3%  
Other income Rs m8974,766 18.8%   
Total revenues Rs m28,605164,475 17.4%   
Gross profit Rs m6,23530,973 20.1%  
Depreciation Rs m1,02713,263 7.7%   
Interest Rs m71,684 0.4%   
Profit before tax Rs m6,09820,791 29.3%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2925,695 40.2%   
Profit after tax Rs m3,80614,924 25.5%  
Gross profit margin %22.519.4 116.0%  
Effective tax rate %37.627.4 137.2%   
Net profit margin %13.79.3 147.0%  
BALANCE SHEET DATA
Current assets Rs m15,922124,266 12.8%   
Current liabilities Rs m6,23537,715 16.5%   
Net working cap to sales %35.054.2 64.5%  
Current ratio x2.63.3 77.5%  
Inventory Days Days6491 70.2%  
Debtors Days Days2195 22.0%  
Net fixed assets Rs m7,539105,190 7.2%   
Share capital Rs m2301,611 14.3%   
"Free" reserves Rs m21,962148,511 14.8%   
Net worth Rs m22,192150,123 14.8%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m29,839239,633 12.5%  
Interest coverage x872.113.3 6,535.7%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.7 139.3%   
Return on assets %12.86.9 184.4%  
Return on equity %17.29.9 172.5%  
Return on capital %27.511.8 232.4%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58757,410 13.2%   
Fx outflow Rs m7,14519,041 37.5%   
Net fx Rs m44238,368 1.2%   
CASH FLOW
From Operations Rs m3,73916,911 22.1%  
From Investments Rs m-731-16,687 4.4%  
From Financial Activity Rs m-1,972-3,487 56.5%  
Net Cashflow Rs m1,036-3,451 -30.0%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 60.4 20.8 290.4%  
Indian inst/Mut Fund % 14.4 12.2 118.0%  
FIIs % 14.6 23.7 61.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   15,184 161,166 9.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 260 Points Lower; Finance and Banking Stocks Witness Huge Selling(Closing)

Indian share markets witnessed negative trading activity today and ended their trading session lower.

Related Views on News

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

Protect Your Wealth from Fund Managers(Fast Profits Daily)

May 14, 2020

Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.

Covid-19 Offers a Rare Opportunity to Own This Brand Leader(Profit Hunter)

May 12, 2020

Covid-19 has compounded uncertainties in investing but this smallcap company is strong enough to survive and even emerge stronger.

Of India's 20 Trillion Stimulus Package and the Swoosh Index for a Swoosh Recovery(Profit Hunter)

May 13, 2020

For India's rapid economic recovery, hopping on to the Swoosh index is a must.

How Commodity Prices Tell You When Stocks Will Go Up(Fast Profits Daily)

May 20, 2020

Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.

Why Buffet - and you - should study Quantum Liquid Fund(The Honest Truth)

May 14, 2020

Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


May 22, 2020 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS